Quarterly Result13 May 2026, 03:51 pm
GSK India: FY26 PAT Up 10% to ₹1012 Cr, Dividend ₹57/Share
AI Summary
GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced its financial results for the year ended 31st March 2026, reporting a 2% revenue growth to ₹3790 crores. Profit After Tax (PAT) increased by 10% to ₹1012 crores, with EBITDA margins expanding by 290 bps to 34%. The Board of Directors recommended a final dividend of ₹57 per equity share. The company's performance was driven by pricing measures, investments in innovative therapies, and cost management. Supply chain disruptions impacted topline growth, prompting efforts to enhance supply chain resilience. The Oncology business saw a key milestone with Jemperli's first-line approval for endometrial cancer.
Key Highlights
- GSK India's FY26 revenue reached ₹3790 crores, a 2% increase year-over-year.
- Profit After Tax (PAT) grew by 10% to ₹1012 crores for FY26.
- EBITDA margins expanded by 290 bps to 34% for the full year.
- A final dividend of ₹57 per equity share was recommended for FY26.
- Jemperli received first-line approval for endometrial cancer in India.